Director sold ~$19.8M of Incyte
Automatic saleLoading…
Traded Oct 15, 2025 · Filed Oct 17, 2025
Incyte's & General Counsel sold $24K of Incyte shares. It happened by itself, for taxes or pay.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$23,581
Shares × reported transaction price
78 days after results of Jul 29, 2025, 13 days before results of Oct 28, 2025
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $88.15 on Oct 15, 2025, at its 52-week high, after a 1% rise over the previous 30 trading days
52-week range $55.17 (Apr 10, 2025) to $88.15 (Oct 15, 2025), 100% of the way up, from 250 adjusted closes. 30 trading days earlier: $86.96 on Sep 3, 2025. Describes the past only, not a forecast
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
FDA approved Opzelura on Sep 18, 2025, 27 days before this trade.
New use approved (efficacy supplement). Active ingredient: Ruxolitinib Phosphate. From openFDA. Dates only; no link between the two is implied
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +8.0% | +2.1% | +5.9% |
| 30 days | +17.6% | -1.3% | +18.9% |
| 90 days | +19.1% | +0.9% | +18.1% |
| 180 days | +12.5% | +5.6% | +6.9% |
Past results only. Not a forecast.
Director sold ~$19.8M of Incyte
Automatic saleDerivative exercise or conversion — not an open-market buy.
Derivative exercise or conversion — not an open-market buy.